_edited.png)
RISK CONCERN
Investment Strategy, Risk Analysis, and Insights by Chartered Professionals
HSIC
Primary Facts
Medical Distribution
Name:
-
Sector:
74.00M
Industry:
71.26
CEO:
Mr. Stanley Bergman
Total Employees:
Mid Cap
Our Technological Advancement Rating
Our Rating:
-0.992887856
1.33227E-15
Henry Schein, Inc. (XNAS:HSIC) In-Depth Stock/Fundamental/Options Analysis Today
Primary Targets/Price Insights
Previous Close ($) :
HENRY SCHEIN, INC. (XNAS:HSIC)
One Month Price Target:
Six Month Price Target :
$71.57
Likely Price in One Year's Time:
Ticker:
$73.09
Likely Trading Range Today Under (Normal Volatility)
$71.54
Price Upper limit ($) :
$74.92
Price Lower limit ($) :
Crash Risk Prep/Key Price Levels (High Volatility/Risk)
Price, as per data analysis, isn't likely to fall below:
Today:
P286
This week:
$68.17
This month :
$64.36
Other Primary facts
Market Cap:
136.11M
Market Cap Classification:
9.70B
Number of Shares
IPO Date:
B
Best/Worst Daily Performance (Last 3+ Years)
Highest Daily Appreciation:
-9.64%
$57.45
Worst Daily Decline:
Our Options Trading Entry Points
Iron Condor entry points for options expiring in 1 week's time
Low risk (<2%) entry points
Buy Call:
Sell Call:
Buy Put:
Sell Put:
$79.03
10.26%
$63.49
$85.59
Medium risk (<10%) entry points
Buy Call
Sell Call
$75.50
Buy Put:
Sell Put:
$56.93
$67.02
$76.90
These entry points can be used for other strategies, such as butterflies, straddles, etc.
Risk-Adjusted returns (Sharpe Ratio) of
Medical Distribution
Sharpe Ratio:
HSIC, is amongst the top 60% highest yielding stocks in terms of daily returns
Comparison:
1.25%
-0.318451355
Sharpe ratio is -31.85% lower than the industry
Average Returns/Yield of
Medical Distribution
Daily returns:
1
Weekly returns:
0.03%
Monthly returns:
0.13%
Yearly returns:
6.48%
Comparison of returns:
-0.336294879
Classification:
Average annual returns/yield (last 3 years) is -33.63% below industry average
Results of T-Test of Returns:
HSIC is a riskier investment compared to Nasdaq (IXIC)
Statistical test of Returns:
0.69
Volatility (measured by Standard Deviation)
Daily Volatility:
& is -62.49% lower than the market/S&P 500 average
Weekly Volatility:
2.12%
Monthly Volatility:
4.75%
Yearly Volatility:
9.49%
Volitlilty of last five days (Measured by Standard Deviation)
Average Volatility of this Week:
41.38%
-53.98%
Value at Risk Analysis (VaR)
Daily VaR:
Volatility in last five trading days has been -53.98% below long-term volatility
Weekly VaR:
-4.33%
Monthly VaR:
-9.69%
How Much Can the price of
Medical Distribution
Decline in a Recession?
Likely price decline in a recession:
Base case (decline):
Risk of crash in next 6/12 months: Medium (<50%)
Worst case (decline):
$59.27
This translates to price declining to:
-17%
This translates to price declining to:
-67.12%
Severe Crash Probability
-19.38%
What is Value at Risk (VaR)?
Risk Fundamentals
17.16%
HSIC is a 36.76% riskier investment compared to the market/S&P 500 & is 17.16% riskier than Nasdaq (IXIC)
HSIC is a 36.76% riskier investment compared to the market/S&P 500
Beta Examination of
Medical Distribution
0.765
Expected beta in 1 year's time:
0.598
Expected beta in 3 year's time:
0.605
Unlevered (debt free) Beta:
Beta in relation to market/S&P 500--0.77
Beta in relation to Nasdaq (XNAS):
Returns are, approximately, symmetrical
Beta in relation to all global stocks::
Beta is -24.38% below industry average
Beta Comparison & Analysis
Beta of competitors/peers::
0.625
-0.259
Average Industry Beta:
Beta is -25.92% lower than peers
-0.24378552
Sustainable Growth Rate Analysis
Sustainable growth rate for this stock/firm:
WACC is -11.13% below industry mean WACC
50.88%
Alpha provided | Alpha Analysis
Alpha provided:
0.855
5.018
-1.217
Analysis of Cost of Capital of
Medical Distribution
Equity cost of capital:
Alpha is -122% below the market average
-0.168
Unlevered (without debt) cost of capital:
Equity cost of capital is -16.76% below industry mean WACC
Before-tax cost of debt:
6.86%
After-tax cost of debt:
2.31%
Overall debt rating:
1.82%
Weighted average cost of capital (WACC):
2.31%
-11.13%
Key Per-Share Metrics & Analysis
Revenue per share:
-
Revenue growth rate per share of (3Y):
Price to sales ratio is 10.38% above the industry mean
-32.45%
EPS:
Six Hundred Thirty-Five Million Thirty-Four Thousand Six Hundred Dollars
Expected Annual growth rate of EPS (3Y):
-
-116.38%
Free cash flow (FCF) per share:
Price to book ratio is -19.24% below the industry mean
-
-
Debt per share
Debt repayment rate in last quarter: 4.81%
EBITDA per share
Each employee generates 8% more EBITDA than industry average revenue per employee
Valuation Analysis Today of
Medical Distribution
P/E Ratio:
Sustainable growth rate is 50.88% above industry average
P/E Ratio of Competitors/Peers:
15.33
-0.152099149
83.14061707
-0.14289787
$4.75
-
P/S (Price to Sales ratio):
$92.97
0.103827067
P/B (Price to book value ratio):
Price to sales ratio is 10.38% above the industry mean
-
-
Net income growth rate (3Y):
Annual revenue growth rate is -32.45% below industry average
1554.42%
Dividend Analysis
Net income growth rate is 1554.42% higher than the average industry net income growth rate
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Dividend History:
-
--$0.00
--$0.00
--$0.00
--$0.00
--$0.00
-
In-depth Debt & Leverage Analysis
Debt to equity ratio:
30.43%
Net debt to equity ratio:
The remaining useful life of property plant & equipment is: 27.6 years
Debt to assets ratio:
12.94%
Net debt to assets ratio:
29.23%
-77.40%
Ability to repay debt:
Interest coverage ratio:
Debt-to-asset ratio is -77.40% below industry average
-0.05
Looking forward:
Debt growth rate:
1.1x
23.60%
4.81%
Analysis of Key Statistics
Correlation of price movement with the market:
14.70278675
Statistical significance of correlation:
-0.33%
Average Correlation of the industry with the market:
0.49
-2.70%
R Squared (percentage of price movement explained by movement of the market):
0.49
Correlation of price movement with Nasdaq (^IXIC):
0.24
Covariance of price movement with the market:
0.024
Kurtosis
0.03
3.969
Skewness of returns:
Returns have moderate fat-tails (leptokurtic), i.e., returns considerably higher or lower than the mean returns are more probable, compared to assets with normally distributed returns
0.041
Fundamental Analysis & Dupont Analysis of
Medical Distribution
Gross Profit Margin Ratio:
3.75B
Operating Profit Margin Ratio:
Net profit margin is 33.90% higher than the industry
79.37%
Net Profit Margin Ratio:
3.75B
Effective Tax Rate:
1.86%
0.037004403
Dupont Method
Net Profit Margin
Return on Equity Ratio (ROE):
×
ROA
=
×
Return on assets (ROA) is 18.17% higher than the industry
2.85%
Financial Leverage
Asset Turnover Ratio (ROA):
Operating profit margin is 79.37% higher than the industry
18.17%
Financial Leverage:
Interest coverage ratio is -5.42% less than industry average
Current Ratio:
Return on equity (ROE) is 2.85% higher than the industry
0.113618852
Cash Conversion Cycle (days):
$7.71
-0.622285726
Current ratio is 11.36% above industry average
Stock based compensation to net income ratio:
-
In-depth Efficiency Analysis
Revenue generated per employee:
Cash conversion cycle is -62.23% below industry average
-0.180561685
EBITDA generated per employee:
Each employee generates -18% less revenue than industry average revenue per employee
0.076886545
Profit generated per employee:
$7.99
6%
Free cash flow (FCF) generated per employee:
Each employee generates 6% more net income/profit than industry average revenue per employee
-1.178991556
Assets/Capital per employee
Each employee generates -118% less free cash flow than industry average revenue per employee
-1.178991556
Research & Development (R&D) Analysis
-
-
Competitors/Peer firms of
Medical Distribution
$121.09
XLRN
Grifols SA (XNAS:GRFS)
BRUKER CORPORATION (XNAS:BRKR)
REPLIGEN CORPORATION (XNAS:RGEN)
NOVAVAX, INC. (XNAS:NVAX)
DENTSPLY SIRONA INC. (XNAS:XRAY)
SYNEOS HEALTH, INC. (XNAS:SYNH)
UNITED THERAPEUTICS CORPORATION (XNAS:UTHR)
Current Analyst Ratings
$4.60
Strong buy�21%
Buy�17%
Hold�29%
Sell�0%
Strong sell�0%
Income Statement
Period:
3/31/2022
Date:
Value
Revenue:
TTM
Cost of Revenue:
Gross Profit:
R&D Expense
General & Admin Expenses:
Selling, General & Admin Expenses
Sales and Marketing Expenses
Other Expenses :
Operating Expenses :
Cost & Expenses :
Interest Income:
Interest Expenses:
Depreciation & Amortization:
EBITDA:
Operating Income:
Other Income Expenses:
Income Before Tax:
Income Tax Expense:
Net Income:
Balance Sheet
Date:
Calendar Year:
Period:
Cash & Cash Equivalents:
Short Term Investments:
Cash & Short Term Investments:
Net Receivables:
Inventory:
Other Current Assets:
Total Current Assets:
PP&E:
Goodwill:
Intangible Assets:
Long Term Investments:
Tax Assets:
Other Non-Current Assets:
Total Non-Current Assets:
Other Assets:
Total Assets:
Accounts Payable:
Short Term Debt:
Tax Payables:
Deferred Revenue:
Other Current Liabilities:
Total Current Liabilities:
Long Term Debt:
Other Non-Current Liabilities:
Total Non Current Liabilities:
Other Liabilities:
Total Liabilities:
Common Stock:
Retained Earnings:
Accumulated Other Comprehensive Loss:
Other Total Stockholders' Equity:
Total Stockholders' Equity:
Total Liabilities and Stockholders' Equity:
Total Investments:
Total Debt:
Net Debt:
12.66B
8.90B
119%
-
-
2.84B
-
47.00M
11.78B
6.47M
28.12M
215.17M
34%
197.66M
- 21915.00K
27%
197.66M
Statement of Cash Flow
Date:
Period:
186.00M
Differed Income Tax :
55.00M
Stock Based Compensation :
1.00M
Change in Working Capital :
12.00M
Accounts Receivables:
- 155000.00K
Other Working Capital:
-
Other Non-Cash Items:
-
Net Cash Provided by Operating Activities:
- 6000.00K
Investments in PP&E:
93.00M
Net Acquisitions:
- 19000.00K
Purchases of Investments:
- 5000.00K
Sales/Maturities of Investments:
Other Investing Activities:
Net Cash Used for Investing Activities:
Debt Repayment:
Common Stock Issued:
Common Stock Repurchased:
Dividend Paid:
Other Financing Activities:
Net Cash Used Provided by Financing Activities:
Effect of FOREX on Changes in Cash:
Net Changes in Cash:
Cash at End of Period:
Cash at Beginning of Period:
Operating Cash Flow:
Capital Expenditure:
Free Cash Flow (FCF):
Value
3/31/2022
2022
Q1
126.00M
-
126.00M
1.44B
1.87B
389.00M
3.83B
689.00M
2.86B
644.00M
427.00M
-
-
4.62B
-
8.45B
914.00M
169.00M
174.00M
-
1.06B
2.14B
1.05B
989.00M
2.08B
-
4.22B
1.00M
3.76B
- 168000.0K
Value
2.88B
-
3.59B
7.82B
-
1.22B
-
-
- 3000.00K
- 27000.00K
- 53000.00K
-
-
-
- 9000.00K
- 62000.00K
4.00M
8.00M
126.00M
118.00M
93.00M
- 19000.00K
Our Proprietary Portfolio Rating
Our Rating:
4.47768E-14
Price Forecast/Expected Price in Next 5 Years of
Medical Distribution
2023
2024
2025
2026
2027
99.08187488
$75.29
$104.18
$109.53
$115.16